Naylor ML, Yun J, Arnold D. No evidence of disease activity achievement over 4 years of peginterferon beta-1a treatment in newly diagnosed patients with relapsing Multiple Sclerosis: subgroup analyses of ADVANCE/ATTAIN. EAN 2018, poster EPR2116.
Dabrafenib plus trametinib bij BRAFV600E-gemuteerd laag- en hooggradig glioom
feb 2022 | Neuro-oncologie